Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1123-1127

  Heidegger, Simon ^a   Beer, Ambros ^a   Geissinger, Eva ^b   Rosenwald, Andreas ^b   Peschel, Christian ^a   Ringshausen, Ingo ^a   Keller, Ulrich ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Anaplastic large cell lymphoma (ALCL); Anti CD30 drug conjugate; Combined therapy; DHAP; Refractory Relapsed lymphoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE DERIVATIVE; BRENTUXIMAB VEDOTIN; CARMUSTINE; CD3 ANTIGEN; CD30 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ALK GENE; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; COUGHING; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; EPIGASTRIC PAIN; GASTROSCOPY; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LYMPH NODE; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NIGHT SWEAT; ORAL BIOPSY; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PROTEIN EXPRESSION; REPEATED DRUG DOSE; SHOULDER PAIN; STOMACH TUMOR; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION; YOUNG ADULT;

EID: 84903163972     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S59795     Document Type: Article

References (24)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
2. Savage KJ, Harris NL, Vose JM, et al; International Peripheral T-Cell Lymphoma Project. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504.
3. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
4. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83-87.
5. Chen X, Soma LA, Fromm JR. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther. 2013;7:45-56.
6. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30(7):631-637.
7. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888-897.
8. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697-2706.
9. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913-3921.
10. Reichard KK, McKenna RW, Kroft SH. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol. 2007;20(3):310-319.
11. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117-122.
12. Gaspard MH, Maraninchi D, Stoppa AM, et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol. 1988;22(3):256-262.
13. Rodriguez J, Caballero MD, Gutiérrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768-1775.
14. Jagasia M, Morgan D, Goodman S, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma. 2004;45(11):2261-2267.
15. Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;23(5):437-442.
16. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
17. Pro B, Advani RH, Brice P, et al. Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2013;122(21):1809.
18. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
19. Duvic M, Tetzlaff M, Clos AL, Gangar P, Talpur R. Results of a phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Abstract presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Blood. 2012;120(21): Abstract 3688.
20. Jacobsen ED, Advani RH, Oki Y, et al. A phase 2 Study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results. Abstract presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA. Blood. 2012;120(21): Abstract 2746.
21. Eichenauer DA, Plütschow A, Kreissl S, et al. Targeted Beacopp variants In patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Abstract presented at: 55th ASH Annual Meeting and Exposition; December 7-10, 2012; New Orleans, LA. Blood. 2013;122(21): Abstract 4344.
22. Moskowitz A, Schoder H, Gerecitano JF, et al. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Abstract presented at: 55th ASH Annual Meeting and Exposition; December 7-10, 2012; New Orleans, LA. Blood. 2013;122(21): Abstract 2099.
23. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348-1356.
24. Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin administered before, during, and after multi-agent chemotherapy in patients (pts) with newly-diagnosed CD30+ mature T-and NK-cell lymphomas. Abstract presented at: 55th ASH Annual Meeting and Exposition; December 7-10, 2012; New Orleans, LA. Blood. 2013;122(21): Abstract 4386.